Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
20M
-
Shares change
-
-41.7K
-
Total reported value, excl. options
-
$158M
-
Value change
-
-$38.3M
-
Number of buys
-
24
-
Number of sells
-
-26
-
Price
-
$7.93
Significant Holders of Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC) as of Q3 2020
66 filings reported holding FULC - Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2020.
Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20M shares
of 54M outstanding shares and own 36.98% of the company stock.
Largest 10 shareholders include TRV GP III, LLC (5.96M shares), TRV GP IV, LLC (2.34M shares), FMR LLC (1.84M shares), Point72 Asset Management, L.P. (1.51M shares), Casdin Capital, LLC (1.44M shares), RTW INVESTMENTS, LP (1.15M shares), BOXER CAPITAL, LLC (706K shares), Alphabet Inc. (678K shares), BlackRock Inc. (659K shares), and Opaleye Management Inc. (452K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.